Tumor Necrosis Factor Receptor Superfamily, Member 9
"Tumor Necrosis Factor Receptor Superfamily, Member 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053261
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.220
|
| Concept/Terms |
Tumor Necrosis Factor Receptor Superfamily, Member 9- Tumor Necrosis Factor Receptor Superfamily, Member 9
- 4-1BB Receptor
- 4 1BB Receptor
- Receptor, 4-1BB
- CD137 Antigen
- Antigen, CD137
- CD137 Antigens
- Antigens, CD137
- TNFRSF9 Receptor
- Receptor, TNFRSF9
- 4-1BB Receptors
- 4 1BB Receptors
- Receptors, 4-1BB
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Receptor Superfamily, Member 9".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Receptor Superfamily, Member 9".
This graph shows the total number of publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 9" by people in this website by year, and whether "Tumor Necrosis Factor Receptor Superfamily, Member 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 9" by people in Profiles.
-
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 May 28; 43(5):114141.
-
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. J Clin Invest. 2020 03 02; 130(3):1405-1416.
-
Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice. Cancer Immunol Res. 2018 11; 6(11):1301-1313.
-
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
-
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 02; 214(2):381-400.
-
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81.
-
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol. 2009 Sep; 39(9):2424-36.
-
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008 Nov 01; 14(21):6895-906.
-
Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J Immunol. 2006 Jul 15; 177(2):814-21.
-
[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases]. An Sist Sanit Navar. 2006 Jan-Apr; 29(1):77-96.